NASDAQ:IRON

Disc Medicine (IRON) Stock Price, News & Analysis

Disc Medicine logo
$76.59 -3.41 (-4.26%)
Closing price 04:00 PM Eastern
Extended Trading
$76.56 -0.03 (-0.03%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Disc Medicine Stock (NASDAQ:IRON)

Advanced

Key Stats

Today's Range
$76.40
▼
$80.37
50-Day Range
$55.74
▼
$87.08
52-Week Range
$40.00
▼
$99.50
Volume
816,009 shs
Average Volume
679,945 shs
Market Capitalization
$3.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$124.18
Consensus Rating
Moderate Buy

Company Overview

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function.

The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease. Disc Medicine is also developing DISC-3405, which targets iron regulation and is being studied for polycythemia vera.

These candidates are in clinical development and are not approved treatments. Disc Medicine was formed through a 2021 business combination involving Disc Medicine and Gemini Therapeutics.

AI Generated. May Contain Errors.

Disc Medicine Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

IRON MarketRank™: 
3.821423836665 of 5 stars

Disc Medicine scored higher than 76% of companies evaluated by MarketBeat, and ranked 128th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Disc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Disc Medicine has a consensus price target of $124.18, representing about 62.1% upside from its current price of $76.62.

  • Amount of Analyst Coverage

    Disc Medicine has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Disc Medicine's stock forecast and price target.
  • Earnings Growth

    Earnings for Disc Medicine are expected to decrease in the coming year, from ($6.20) to ($6.30) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Disc Medicine is -12.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Disc Medicine is -12.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Disc Medicine has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    18.57% of the float of Disc Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Disc Medicine has a short interest ratio ("days to cover") of 3.18, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Disc Medicine has recently decreased by 7.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Disc Medicine does not currently pay a dividend.

  • Dividend Growth

    Disc Medicine does not have a long track record of dividend growth.

  • News Sentiment

    Disc Medicine has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Disc Medicine this week, compared to 8 articles on an average week.
  • Search Interest

    10 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,489,009.00 in company stock.

  • Percentage Held by Insiders

    3.76% of the stock of Disc Medicine is held by insiders.

  • Percentage Held by Institutions

    83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Disc Medicine's insider trading history.
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRON Stock News Headlines

HC Wainwright Raises Earnings Estimates for Disc Medicine
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Disc Medicine (NASDAQ:IRON) Stock Rating Upgraded by Wall Street Zen
See More Headlines

IRON Stock Analysis - Frequently Asked Questions

Disc Medicine's stock was trading at $79.41 at the beginning of the year. Since then, IRON stock has decreased by 3.5% and is now trading at $76.62.

Disc Medicine, Inc. (NASDAQ:IRON) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($1.63) by $0.10.

Disc Medicine (IRON) raised $105 million in an initial public offering (IPO) on Wednesday, August 12th 2020. The company issued 10,500,000 shares at $10.00 per share.

Top institutional shareholders of Disc Medicine include State Street Corp (3.66%), Assenagon Asset Management S.A. (2.92%), Aberdeen Group plc (1.56%) and Checkpoint Capital L.P. (0.88%). Insiders that own company stock include Venture Fund X LP Atlas, Orbimed Advisors Llc, John D Quisel, Mona Ashiya, Pamela Stephenson, Jean M Franchi, William Jacob Savage, Jonathan Yen-Wen Yu, Rahul Khara, Kevin Bitterman, Joanne Bryce and William Richard White.
View institutional ownership trends
.

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Dell Technologies (DELL), Ford Motor (F), Oracle (ORCL), Occidental Petroleum (OXY) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

Last Earnings
11/05/2026
Today
11/16/2026
UBS Global Biopharma Conference 2026
11/17/2026
Jefferies Global Healthcare Conference
11/18/2026
Investor update
12/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IRON
CIK
1816736
Fax
N/A
Employees
165
Year Founded
2017

Price Target and Rating

High Price Target
$170.00
Low Price Target
$92.00
Potential Upside/Downside
+62.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$212.18 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-36.33%
Return on Assets
-32.50%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
20.30
Quick Ratio
20.30

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$19.52 per share
Price / Book
3.92

Miscellaneous

Outstanding Shares
45,541,000
Free Float
43,829,000
Market Cap
$3.49 billion
Optionable
Optionable
Beta
0.96

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:IRON) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners